|
Re: BET inhibitors RVX-208 and PFI-1 reactivate HIV-1 from latency
|
3
|
Resverlogix Corp.
|
Dec 05, 2017 08:22PM
|
|
Re: Apabetalone and Alkaline Phosphatase
|
3
|
Resverlogix Corp.
|
Oct 12, 2019 09:22PM
|
|
Amgen's Repatha (Evolocumab) Reduces MACE Events In FOURIER Trial
|
3
|
Resverlogix Corp.
|
Feb 02, 2017 05:28PM
|
|
Re: Roth research report
|
3
|
Resverlogix Corp.
|
Nov 01, 2018 09:47AM
|
|
Re: The waiting game.....
|
3
|
Resverlogix Corp.
|
Feb 12, 2019 05:53PM
|
|
Re: Resverlogix Cognition Substudy of the BETonMACE Phase 3 Cardiovascular Trial Presented at the International AD/PD Conference
|
3
|
Resverlogix Corp.
|
Apr 01, 2019 01:29PM
|
|
Re: Financial Future
|
3
|
Resverlogix Corp.
|
May 13, 2019 03:05PM
|
|
Zenith Epigenetics Announces Dosing of First mCRPC Patient with a Combination of ZEN-3694 + Merck’s Immune Check Point Inhibitor KEYTRUDA
|
3
|
Zenith Epigenetics
|
Mar 15, 2021 01:16PM
|
|
Re: Monday!
|
3
|
Resverlogix Corp.
|
Sep 26, 2019 10:15PM
|
|
Re: ONT-380
|
3
|
Resverlogix Corp.
|
Feb 04, 2016 03:38PM
|
|
Re: Will we see 5 point MACE reduction results in BETONMACE
|
3
|
Resverlogix Corp.
|
Jun 17, 2019 05:28PM
|
|
Re: ...is anybody out there at the AGM...?
|
3
|
Resverlogix Corp.
|
Sep 30, 2015 11:50PM
|
|
Re: Resverlogix Presents at Clinical Trials in Alzheimer’s Disease (CTAD) Asia 2018
|
3
|
Resverlogix Corp.
|
Sep 04, 2018 01:01PM
|
|
Re: BiOasis Presents at BIO Investor Forum Oct 17th
|
3
|
BIOASIS TECHNOLOGIES INC
|
Oct 17, 2018 07:59PM
|
|
Re: Finally some news
|
3
|
BIOASIS TECHNOLOGIES INC
|
Apr 11, 2022 04:31PM
|
|
Re: NEW NR
|
3
|
Resverlogix Corp.
|
Aug 04, 2015 10:59AM
|
|
Re: ...why it's a "Showdown in Stockholm”...
|
3
|
Resverlogix Corp.
|
Aug 22, 2015 07:34AM
|
|
Re: Some idle speculation I just can't resist.....
|
3
|
Resverlogix Corp.
|
Aug 26, 2016 11:34AM
|
|
Re: Zenith Epigenetics Announces Dosing of First mCRPC Patient with a Combination of ZEN-3694 + Merck’s Immune Check Point Inhibitor KEYTRUDA
|
3
|
Zenith Epigenetics
|
Mar 15, 2021 01:22PM
|
|
Re: Breakthrough Therapy Designation Application
|
3
|
Resverlogix Corp.
|
Dec 06, 2019 11:58AM
|
